Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 4
Submit an article Journal homepage
837
Views
5
CrossRef citations to date
0
Altmetric
Short Report

Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series

Masato TakeuchiDepartment of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2990-2687View further author information
ORCID Icon &
Koji KawakamiDepartment of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, JapanORCID Iconhttps://orcid.org/0000-0002-7477-4071View further author information
ORCID Icon
Pages 1235-1238 | Received 29 May 2020, Accepted 07 Aug 2020, Published online: 22 Sep 2020

References

  • Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al.; RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946–58. doi:10.1016/S0140-6736(17)30938-8.
  • American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620–638. doi:10.1542/peds.2014-1666.
  • Mitra S, El Azrak M, McCord H, Paes BA. Hospitalization for respiratory syncytial virus in children with Down syndrome less than 2 years of age: a systematic review and meta-analysis. J Pediatr. 2018;203:92–100.e3. doi:10.1016/j.jpeds.2018.08.006.
  • Mori M, Morio T, Ito S, Morimoto A, Ota S, Mizuta K, Iwata T, Hara T, Saji T. Risks and prevention of severe RS virus infection among children with immunodeficiency and Down’s syndrome. J Infect Chemother. 2014;20:455–59. doi:10.1016/j.jiac.2014.05.001.
  • Kimura T, Takeuchi M, Kawakami K. Utilization and efficacy of palivizumab for children with Down syndrome. Pediatr Int. 2020;62(6):677–82. [Epub ahead of print]. doi:10.1111/ped.14157.
  • Takeuchi M, Ito S, Nakamura M, Kawakami K. Changes in hemoglobin concentrations post-immunoglobulin therapy in patients with Kawasaki disease: a population-based study using a claims database in Japan. Paediatr Drugs. 2018;20:585–91. doi:10.1007/s40272-018-0316-y.
  • Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46:348–55. doi:10.1093/ije/dyw098.
  • Alsubie HS, Rosen D. The evaluation and management of respiratory disease in children with Down syndrome (DS). Paediatr Respir Rev. 2018;26:49–54. doi:10.1016/j.prrv.2017.07.003.
  • Bloemers BL, Broers CJ, Bont L, Weijerman ME, Gemke RJ, van Furth AM. Increased risk of respiratory tract infections in children with Down syndrome: the consequence of an altered immune system. Microbes Infect. 2010;12:799–808. doi:10.1016/j.micinf.2010.05.007.
  • Paes B, Mitchell I, Yi H, Li A, Lanctôt KL; CARESS Investigators. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J. 2014;33:e29–33. doi:10.1097/INF.0000000000000019.
  • Simon A, Gehrmann S, Wagenpfeil G, Wagenpfeil S. Palivizumab use in infants with Down syndrome-report from the German Synagis™ registry 2009–2016. Eur J Pediatr. 2018;177:903–11. doi:10.1007/s00431-018-3142-x.
  • Yi H, Lanctôt KL, Bont L, Bloemers BL, Weijerman M, Broers C; CARESS investigators. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Pediatrics. 2014;133:1031–37.
  • Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13:2138–49. doi:10.1080/21645515.2017.1337614.
  • Yi H, Lanctôt KL, Bont L, Bloemers BLP, Weijerman M, Broers C, Li A, Kiss A, Mitchell I, Paes B. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Pediatrics. 2014;133:1031–37. doi:10.1542/peds.2013-3916.
  • Cui L, Zhang L. On the efficiency of adaptive sample size design. Stat Med. 2019;38:933–44. doi:10.1002/sim.8034.
  • Bjornson C, Chan P, Li A, Paes B, Lanctôt KL, Mitchell I. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need? Eur J Clin Microbiol Infect Dis. 2018;37:1113–18. doi:10.1007/s10096-018-3225-7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.